Document:

Exhibit 10.24

 

SECOND AMENDMENT AND LEASE CONSOLIDATION

 

This Second Amendment and Lease Consolidation (the “Second Amendment”) is entered into as of this 30th day of September, 2011, by and between Laguna Cabot Road Business Park, LP (“Landlord”), and Glaukos Corporation (“Tenant”), with reference to the following recitals.

 

R E C I T A L S:

 

A.                                    Landlord is the successor-in-interest to PRI SA Acquisitions, LLC, the “Previous Owner.”

 

B.                                    Tenant occupies 26051 Merit Circle, Suites 103 and 104, Laguna Hills, CA (the “Original Premises”) and Suite 105 (the “Expansion Premises”) Together, the Original Premises and the Expansion Premises shall be referred to herein as the “Premises.” The Premises are a part of 26051 Merit Circle, Laguna Hills, CA, a multi-tenant building (the “Building”).

 

C.                                    On or about October 1, 2005, the Previous Owner and Tenant entered into a Standard Business Park Lease — Multi-Tenant for the Original Premises, which was subsequently amended by the First Amendment to Lease dated October 8, 2008 (together the “Original Lease”). On or about November 9, 2009, Landlord and Tenant entered into a Standard Business Park Lease — Multi-Tenant for the Expansion Premises (the “Expansion Lease”).

 

D.                                    Landlord and Tenant wish to consolidate the Original Lease and the Expansion Lease into one document, hereinafter referred to as the “Consolidated Lease,” and to amend the terms and conditions as set forth below.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

 

1.                                      Effective Date. Effective October 1, 2011, the Original Lease and the Expansion Lease will be combined into the Consolidated Lease and this Second Amendment shall modify and amend the Consolidated Lease (together, the “Lease”). See the Conflict section below for clarification.

 

2.                                      Premises Address. 26051 Merit Circle, Suites 103, 104 and 105, Laguna Hills, CA. (Note-the Premises Address is the mailing address. The Premises are actually located in the City of Mission Viejo.)

 

3.                                      Premises Area. 20,800 square feet.

 

4.                                      Expiration Date. March 31, 2016.

 

5.                                      Base Rent. Monthly Base Rent under the Lease shall be as follows:

 

	
April 1, 2012 to   March 31, 2013
    	
 
    	
$
    	
24,960.00
    	
 
    
	
April 1, 2013 to   March 31, 2014
    	
 
    	
$
    	
26,000.00
    	
 
    
	
April 1, 2014 to   March 31, 2015
    	
 
    	
$
    	
27,040.00
    	
 
    
	
April 1, 2015 to   March 31, 2016
    	
 
    	
$
    	
28,080.00
    	
 
    

 

 

6.                                      CAM Charge. $2,080.00 per month as described in section 4.4 of the Lease.

 

7                                         Inducement Provisions. Tenant shall be entitled to the following Inducement Provisions:

 

A.                                    Free rent in the total amount of $31,572, to be applied in equal installments against the monthly Base Rent beginning October 2011 and ending March 2012 ($31,572 / 6 months = $5,262 per month).

 

B.                                    Allowance to be used for tenant improvements in the amount of $104,000.00, to be paid as a deduction against monthly Base Rent beginning April 2012 ($12,480 per month from April 2012 through November 2012 and $4,160 for December 2012).

 

8.                                      Clean Room. Tenant will be responsible for all costs associated with the installation, maintenance and removal of Tenant’s clean rooms upon the expiration of the Lease. Tenant may request Landlord’s permission to leave the clean rooms intact by sending Landlord a written request no earlier than six months before the Expiration Date and no later than two months before the Expiration Date. Landlord may agree to leave the clean rooms intact, in its sole and absolute discretion, by replying in writing within thirty days of receiving the request.

 

9.                                      HVAC Equipment. Landlord shall, at its sole cost, be responsible for maintaining, repairing, and replacing the HVAC equipment (including but not limited to the compressors) that serve the Premises unless the repairs, maintenance or replacement is caused by Tenant’s willful misuse or abuse. Maintenance, repairs or replacement of any HVAC equipment exclusively serving the clean rooms or computer server room shall be Tenant’s responsibility at its sole cost.

 

10.                               Option to Extend. Tenant shall have the option to extend the lease for one 2-year term in accordance with the terms and conditions of the Option to Extend in section 1.5 of the Expansion Lease. if exercised, the Extension Option will commence April 1, 2016. The arbitration provisions referred to in section 1.5 should refer to section 1.5.1 instead of section 3.09.

 

11.                               Right of Offer. Tenant shall have a Right of Offer as defined on the attached Exhibit E.

 

12.                               Deletions. Section 3.08 is hereby deleted from the Original Lease. Sections 1.6, 1.11, 1.12 and 1.13 are hereby deleted from the Expansion Lease.

 

13.                               Condition. Tenant acknowledges that it is currently in possession of the Leased Premises and therefore accepts the Leased Premises “as is” in accordance with section 3.1 of the Lease. Tenant hereby acknowledges and agrees that the Lease is in full force and effect, Landlord is not currently in default under the Lease, and, to the best of Tenant’s knowledge, no event has occurred which, with the giving of notice or the passage of time, or both, would ripen into Landlord’s default under the Lease. Landlord acknowledges that Tenant has not yet received the Tenant Improvement Allowance payable in accordance with section 1.8 of the Expansion Lease.

 

2

 

14.                               Conflict. If there is a conflict between the terms and conditions of the Original Lease and the Expansion Lease, the terms and conditions of the Expansion Lease shall control. If there is a conflict between the terms and conditions of the Consolidated Lease and the Second Amendment, the terms and conditions of the Second Amendment shall control. Except as modified by this Second Amendment, the terms and conditions of the Consolidated Lease shall remain in full force and effect. Any terms of the Original Lease that would survive the expiration of the Original Lease shall apply to the Original Premises after September 30, 2011, as if the Original Lease had been terminated. Capitalized terms included in this Second Amendment shall have the same meaning as capitalized terms in the Consolidated Lease unless otherwise defined herein.

 

15.                               Authority. The persons executing this Second Amendment on behalf of the parties hereto represent and warrant that they have the authority to execute this Second Amendment on behalf of said parties and that said parties have authority to enter into this Second Amendment.

 

16.                               Brokers. Tenant and Landlord each represent and warrant to the other that neither has had any dealings or entered into any agreements with any person, entity, broker or finder other than Davis Broker, Inc. and CB Richard Ellis in connection with the negotiation of this Second Amendment, that no other broker, person, or entity is entitled to any commission or finder’s fee in connection with the negotiation of this Second Amendment, and that Tenant and Landlord each agree to indemnify, defend and hold the other harmless from and against any claims, damages, costs, expenses, attorneys’ fees or liability for compensation or charges which may be claimed by any such unnamed broker, finder or other similar party by reason of any dealings, actions or agreements of the indemnifying party.

 

17.                               Confidentiality. Tenant acknowledges and agrees that the terms of this Second Amendment are confidential and constitute proprietary information of Landlord. Disclosure of the terms hereof could adversely affect the ability of Landlord to negotiate other leases with respect to the property and may impair Landlord’s relationship with other tenants of the property. Tenant agrees that it and its partners, officers, directors, employees, brokers, and attorneys, if any, shall not disclose the terms and conditions of this Second Amendment to any other person or entity without the prior written consent of Landlord which may be given or withheld by Landlord, in Landlord’s sole discretion. It is understood and agreed that damages alone would be an inadequate remedy for the breach of this provision by Tenant, and Landlord shall also have the right to seek specific performance of this provision and to seek injunctive relief to prevent its breach or continued breach.

 

18.                               Counterparts. This Second Amendment may be executed in counterparts. Each counterpart shall be deemed an original, and all counterparts shall be deemed the same instrument with the same effect as if all parties hereto had signed the same signature page.

 

19.                               Delivery of Amendment. Preparation of this Second Amendment by Landlord or Landlord’s agent and submission of same to Tenant shall not be deemed an offer by Landlord to enter into this Second Amendment. This Second Amendment shall become binding upon Landlord only when fully executed by all parties and when Landlord has delivered a fully-executed original of this Second Amendment to Tenant.

 

3

 

20.                               Notices. All notices provided by Tenant to Landlord pursuant to the Lease shall be sent to the following addresses:

 

Davis Partners
 1420 Bristol Street North, Suite
 100 Newport Beach, California 92660
 Attention: Mark Buchanan

 

and

 

Davis Partners
 26072 Merit Circle, Suite 118
 Laguna Hills, CA 92653
 Attention: Eileen Adams

 

21.                               Additional Exhibits. Exhibit D is a site plan showing the location of the Leased Premises and Exhibit E is the Right of Offer.

 

4

 

IN WITNESS WHEREOF, the parties hereby execute this Second Amendment as of the date first written above.

 

	
 
    	
LANDLORD:
    
	
 
    	
 
    
	
 
    	
Laguna   Cabot Road Business Park, LP
    
	
 
    	
By:   Davis Realty Partners, Agent
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Mark T. Buchanan
    
	
 
    	
Name:
    	
Mark   T. Buchanan, Principal
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
TENANT*:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Glaukos   Corporation, a Delaware corporation
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Thomas W. Burns
    
	
 
    	
Name:
    	
Thomas   W Burns, President and CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Michael Sanders
    
	
 
    	
Name:
    	
Michael   Sanders, Assistant Secretary
    

 

*Authorized officers must sign on behalf of the corporation and indicate the capacity in which they are signing. The amendment must be executed by the president or vice president and the secretary or assistant secretary, unless the bylaws or a resolution of the board of directors shall otherwise provide, in which event, the bylaws or a certified copy of the resolution, as the case may be, must be attached to this amendment.

 

5

 

EXHIBIT E

 

Right of Offer

 

(a)                                 Effective at commencement of this Second Amendment and during the term of this Lease, Tenant shall have the right of offer to lease any premises located in the Building which becomes vacant or Landlord determines will become vacant (the “Additional Premises”). Prior to leasing any Additional Premises, Landlord shall give Tenant written notice of its intent to lease the Additional Premises (a “Landlord Notice”). Tenant shall have fifteen (15) days after Landlord has given written notice in which to provide Landlord with written notice (an “Election Notice”) of its election to exercise its right to lease all of the Additional Premises (Tenant shall not have the right to elect to lease part of the Additional Premises). Tenant shall pay Base Rent for the Additional Premises at the “Market Rate” (as defined below). All of the other terms and conditions pertaining to the lease of the Additional Premises shall be agreed to by Landlord and Tenant within five (5) days after Landlord receives Tenant’s written notice. If Landlord and Tenant are unable to agree on such terms and conditions within the five (5) day period, Tenant’s right to lease the Additional Premises shall automatically expire and Tenant shall have no further right to lease the Additional Premises. All of the terms and conditions for the lease of the Additional Premises shall be satisfactory to Landlord, in Landlord’s sole discretion. If Tenant does not give Landlord written notice of its election to lease such Additional Premises within fifteen (15) days after Landlord gives Tenant its written notice of the availability of the Additional Premises, Landlord shall thereafter be free to lease such Additional Premises to a third party on any terms and conditions that Landlord shall select, with no further obligation to Tenant. In the event that Landlord offers any space to Tenant pursuant to this right of offer and Tenant does not lease the space, the space so offered shall no longer be subject to this right of offer and thereafter Landlord shall not be obligated to offer said space to Tenant. If Landlord unintentionally fails to provide a Landlord Notice to Tenant, Tenant’s sole remedy for such failure shall be to notify Landlord of the failure and to request that it be provided a Landlord Notice, and, in this event, if the Additional Premises is still available for lease (i.e., it has not been leased by Landlord to a another tenant), Landlord shall provide the Landlord Notice to Tenant. Under no circumstances shall Landlord have any legal liability to Tenant (for damages or otherwise) due to Landlord’s unintentional failure to provide a Landlord Notice to Tenant. Landlord shall not be obligated to provide Tenant with notice pursuant to this section, and Tenant shall not have the right to exercise the right of offer granted in this section, at any time that Tenant has subleased all or any portion of the Premises or at any time Tenant is in default as defined in the Lease. This right of offer shall be subject to (i) the prior and existing rights of the other tenants in the Project to lease the Additional Premises and (ii) Landlord’s right, in Landlord’s sole discretion, to elect to renew or extend the lease of any tenant occupying the Additional Premises, whether or not such tenant has the legal right or option to renew or extend its lease.

 

(b)                                 The term “Market Rate” shall mean the annual amount per rentable square foot that a willing, comparable tenant would pay and a willing, comparable landlord of a similar industrial building would accept at arm’s length for similar space, giving appropriate consideration to the following matters: (i) annual rental rates per rentable square foot; (ii) the

 

 

type of escalation clauses (including, but without limitation, operating expense, real estate taxes, and CPI) and the extent of liability under the escalation clauses (i.e., whether determined on a “net lease” basis or by increases over a particular base year or base dollar amount); (iii) rent abatement provisions reflecting free rent and/or no rent during the lease term; (iv) length of lease term (to be determined by Landlord in accordance with (a) above, in Landlord’s sole discretion); (v) size and location of premises being leased; (vi) the amount of any tenant improvement allowance; and (vii) other generally applicable terms and conditions of tenancy for similar space.

 

(c)                                  If Tenant exercises the Right of Offer, Landlord shall determine the Market Rate by using its good faith judgment. Landlord shall provide Tenant with written notice of such amount within five (5) days after Tenant delivers its Election Notice to Landlord. Tenant shall have fifteen (15) days (“Tenant’s Review Period”) after receipt of Landlord’s notice of the rental rate within which to accept such rental. In the event Tenant fails to accept in writing such rental proposal by Landlord, then such proposal shall be deemed rejected, and Landlord and Tenant shall attempt to agree upon such Market Rate, using their best good faith efforts. If Landlord and Tenant fail to reach agreement within seven (7) days following Tenant’s Review Period (“Outside Agreement Date”), then each party shall place in a separate sealed envelope their final proposal as to the Market Rate, and such determination shall be submitted to arbitration in accordance with subsections (i) through (v) below.

 

(ii)                                  Landlord and Tenant shall meet with each other within three (3) business days after the Outside Agreement Date and exchange their sealed envelopes and then open such envelopes in each other’s presence. If Landlord and Tenant do not mutually agree upon the Market Rate within one (1) business day of the exchange and opening of envelopes, then, within three (3) business days of the exchange and opening of envelopes, Landlord and Tenant shall agree upon and jointly appoint a single arbitrator who shall by profession be a real estate broker or agent who shall have been active over the five (5) year period ending on the date of such appointment in the leasing of commercial buildings similar to the Premises in the geographical area of the Premises. Neither Landlord nor Tenant shall consult with such broker or agent as to his or her opinion as to the Market Rate prior to the appointment. The determination of the arbitrator shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Market Rate for the Additional Premises is the closest to the actual Market Rate for the Additional Premises as determined by the arbitrator, taking into account the requirements for determining Market Rate set forth herein. In addition, Landlord or Tenant may submit to the arbitrator with a copy to the other party within three (3) business days after the appointment of the arbitrator any market data and additional information such party deems relevant to the determination of the Market Rate (“RR Data”), and the other party may submit a reply in writing within two (2) business days after receipt of such RR Data.

 

(ii)                                  The arbitrator shall, within three (3) business days of his or her appointment, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Market Rate and shall notify Landlord and Tenant of such determination.

 

(iii)                               The decision of the arbitrator shall be final and binding upon Landlord and Tenant.

 

 

(iv)                              If Landlord and Tenant fail to agree upon and appoint an arbitrator, then the appointment of the arbitrator shall be made by the presiding judge of the Superior Court for the County in which the Premises is located, or, if he or she refuses to act, by any judge having jurisdiction over the parties.

 

(v)                                 The cost of the arbitration shall be paid by Landlord and Tenant equally.

 

(d)                                 The Additional Premises shall be leased to Tenant pursuant to a new and separate lease agreement (the “New Lease”) to be agreed to by Landlord and Tenant. The Additional Premises shall not be added to the Premises leased pursuant to the Lease. Tenant acknowledges and agrees that Landlord shall have no obligation to include in the New Lease any term or condition contained in this Lease. By way of example and not limitation, Landlord shall have no obligation to agree to a coterminous term for the New Lease and this Lease or to provide Tenant with any options to extend the term of the New Lease. Except for the Market Rate which shall be decided in accordance with (b) above, all of the terms and conditions of the New Lease shall be satisfactory to Landlord and Tenant in each of their sole and absolute discretion’s. The consequence of Landlord and Tenant not being able to agree on the terms and conditions of the New Lease shall be that Landlord shall have no further obligation to lease the Additional Premises to Tenant and Tenant shall have no further obligation to lease the Additional Premises from Landlord pursuant to this section.Exhibit 10.25

 

ASSET PURCHASE AGREEMENT

 

This Asset Purchase Agreement, dated as of July 10, 2014, is made by and between DOSE Medical Corporation, a Delaware corporation (“Seller”), and Glaukos Corporation, a Delaware corporation (“Purchaser”), with reference to the following facts:

 

A.                                    Seller holds certain assets and patents described on Exhibit A attached hereto (the “Assets”).

 

B.                                    Seller desires to sell to Purchaser, and Purchaser desires to acquire from Seller, the Assets on the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the parties hereto hereby agree as follows:

 

1.                                      Sale of Assets.  Subject to the terms and conditions set forth herein, at the Closing (as hereinafter defined), Seller shall sell, transfer, assign, convey and deliver to Purchaser, and Purchaser shall acquire and purchase from Seller, all of Seller’s right, title and interest in and to the assets described on Exhibit A attached hereto (the “Assets”).  Except for the Assets set forth on Exhibit A attached hereto, Seller is not selling to Purchaser, nor is Purchaser acquiring or purchasing from Seller, any assets of Seller.

 

2.                                      Excluded Liabilities.  Notwithstanding anything in this Agreement to the contrary, Purchaser is not assuming, and shall not assume, at the Closing or otherwise, and shall not be responsible to pay, perform or discharge, any liabilities, obligations or commitments of any nature whatsoever (asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise) of Seller.

 

3.                                      Consideration. The consideration for the Assets shall be $15,000,000 (“Cash Consideration”) plus the forgiveness of all Indebtedness (as defined below) of Seller to Purchaser outstanding as of the Closing.  At the Closing, Purchaser shall pay Seller the Cash Consideration by check or wire transfer of immediately available funds to such account as Seller may specify to Purchaser.  For purposes of the preceding sentence, “Indebtedness” shall mean the indebtedness represented by that certain promissory note, dated May 6, 2010, made by Seller in favor of Purchaser and the indebtedness of Seller to Purchaser reflected in the intercompany receivable account relating thereto on the financial books and records of Purchaser.

 

4.                                      Allocation of Consideration.  Seller and Purchaser agree that the consideration for the Assets shall be allocated among the Assets for all purposes (including tax and financial accounting purposes) as shown on the allocation schedule attached hereto as Exhibit B.

 

5.                                      Closing. Subject to the terms and conditions set forth herein, the consummation of the transactions contemplated by this Agreement (the “Closing”) shall take place at the offices of Reed Smith LLP, 1901 Avenue of the Stars, Suite 700, Los Angeles, California 90067 immediately following the satisfaction or waiver of all of the conditions to the Closing set forth

 

 

in Section 8 below (other than conditions which, by their nature, are to be satisfied at the Closing or on the Closing Date) or on such other date or at such other time and place as may be agreed to by the parties to this Agreement.

 

6.                                      Closing Deliverables.  At the Closing:

 

(a)                                 Seller shall deliver to Purchaser:

 

(i)                                     a bill of sale in form and substance reasonably satisfactory to Purchaser and duly executed by Seller;

 

(ii)                                  a Patent Assignment in substantially the form attached hereto as Exhibit C for each patent assigned hereby, duly executed on behalf of Seller (individually, a “Patent Assignment”);

 

(iii)                               an Amended and Restated Transition Services Agreement, amending and restating that certain Transition Services Agreement, dated as of March 30, 2010, as amended to date, in substantially the form attached hereto as Exhibit D (the “TSA”), duly executed on behalf of Seller; and

 

(iv)                              an Amended and Restated Patent License Agreement in substantially the form attached hereto as Exhibit E (the “Amended and Restated Patent License Agreement”), duly executed on behalf of Seller.

 

(b)                                 Purchaser shall deliver to Seller:

 

(i)                                     the Cash Consideration;

 

(ii)                                  a Patent Assignment for each patent assigned hereby, duly executed on behalf of Purchaser;

 

(iii)                               the TSA, duly executed on behalf of Purchaser; and

 

(iv)                              the Amended and Restated Patent License Agreement, duly executed on behalf of Purchaser.

 

7.                                      Representations and Warranties.

 

(a)                                 Seller hereby represents and warrants to Purchaser as follows, which representations and warranties shall terminate at the Closing:

 

(i)                                     Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and is qualified to transact business and in good standing in the State of California. Seller has the corporate power and authority to own and operate its properties and assets and to carry on its business as now being conducted.

 

(ii)                                  Subject to stockholder approval and any required consents of the other parties to the Assumed Contracts, Seller has the requisite corporate power and authority to enter

 

2

 

into this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  This Agreement is a valid and binding obligation of Seller enforceable against it in accordance with its terms except (A) as the same may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights and (B) for limitations imposed by general laws of equity.

 

(iii)                               Seller has good title to, or a valid leasehold interest in, the Assets, free and clear of liens and encumbrances other than liens for taxes not yet due and payable and liens arising under equipment leases with third parties entered into in the ordinary course of business.

 

(b)                                 Purchaser hereby represents and warrants to Seller as follows, which representations and warranties shall terminate at the Closing:

 

(i)                                     Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and is qualified to transact business and in good standing in the State of California. Purchaser has the corporate power and authority to own and operate its properties and assets and to carry on its business as now being conducted.

 

(ii)                                  Subject to stockholder approval, any required consents of lenders to Purhcaser and any required consents of the other parties to the Assumed Contracts, Purchaser has the requisite corporate power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby.  This Agreement is a valid and binding obligation of Purchaser enforceable against it in accordance with its terms except (A) as the same may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights and (B) for limitations imposed by general laws of equity.

 

8.                                      Conditions to Closing.

 

(a)                                 The obligations of Seller and Purchaser to sell and acquire, respectively, the Assets on the terms and conditions set forth herein are subject to the fulfillment, at or prior to the Closing, of the following conditions, any of which may be waived in whole or in part by the parties hereto:

 

(i)                                     Purchaser shall have consummated, on or before June 30, 2015, a firm commitment underwritten initial public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, covering the offer and sale of shares of the common stock, par value $0.001 per share, of Purchaser; and

 

(ii)                                  No action or proceeding before any court, governmental body or agency shall have been threatened in writing, asserted or instituted to restrain or prohibit the sale of the Assets or the carrying out of the transactions contemplated by this Agreement.

 

(b)                                 The obligation of Seller to sell the Assets to Purchaser on the terms and conditions set forth herein is subject to the fulfillment, at or prior to the Closing, of the following conditions:

 

3

 

(i)                                     the approval by the stockholders of Seller of sale of the Assets as contemplated this Agreement by the requisite vote thereof as may be required under the DGCL; and

 

(ii)                                  the representations and warranties of Purchaser set forth herein shall be materially true and correct as of the Closing (which condition may be waived in whole or in part in the sole discretion of Seller).

 

(c)                                  The obligation of Purchaser to acquire and purchase the Assets on the terms and conditions set forth herein is subject to the fulfillment, at or prior to the Closing, of the following conditions:

 

(i)                                     the approval by the stockholders of Purchaser of this Agreement by the requisite vote thereof as may be required under the DGCL, Purchaser’s restated certificate of incorporation (as amended to date) and that certain Fourth Amended and Restated Investors’ Rights Agreement, dated as of January 25, 2011, among Purchaser and certain stockholders of Purchaser (as amended to date); and

 

(ii)                                  the representations and warranties of Seller set forth herein shall be materially true and correct as of the Closing (which condition may be waived in whole or in part in the sole discretion of the Purchaser).

 

9.                                      Termination of Agreement.  At any time prior to the Closing, this Agreement may be terminated or abandoned by the mutual written consent of Purchaser and Seller (or the board of directors of either or both such entities) without further action by the stockholders of either such entity (subject to the rights, if any, of third parties under contract relating hereto) notwithstanding that this Agreement and/or the transaction contemplated hereby have been authorized or consented to by the stockholders of both or either of Purchaser or Seller.

 

10.                               Further Assurances.  From time to time after the Closing, Seller shall execute and deliver to Purchaser any such further instruments of sale, conveyance, transfer and assignment and take all such other actions and execute all such other instruments and documents as Purchaser may reasonably request as may be necessary or appropriate in order to vest in Purchaser all right, title and interest of Seller in and to any of the Assets or to more effectively convey and transfer to Purchaser’s possession any of the Assets and all licenses and permits necessary for the operation of the Assets, including without limitation, all assignment documents to be filed with the U.S. Patent and Trademark Office.

 

11.                               Miscellaneous.

 

(a)                                 The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto (or their respective successors and assigns) any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(b)                                 This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be

 

4

 

performed entirely within California, without reference to principles of conflict of laws or choice of laws

 

(c)                                  This Agreement may be executed in any number of counterparts which together shall constitute one and the same instrument.  Delivery of an executed counterpart of a signature page by facsimile shall be effective as delivery of a manually executed counterpart.

 

(d)                                 This Agreement and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.

 

(e)                                  This Agreement may only be amended, supplemented or modified by an instrument in writing executed on behalf of each of the parties hereto.  No waiver by any party of any of the provisions of this Agreement shall be effective unless explicitly set forth in writing and signed by the party so waiving.  No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from under this Agreement shall operate or be construed as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof of the exercise of any other right, remedy, power or privilege.

 

(f)                                   If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.

 

[SIGNATURE PAGE FOLLOWS]

 

5

 

IN WITNESS WHEREOF, this Asset Purchase Agreement has been executed on and as of the date first above written.

 

	
 
    	
SELLER:
    
	
 
    	
 
    
	
 
    	
DOSE   MEDICAL CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Richard L. Harrison
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
PURCHASER:
    
	
 
    	
 
    
	
 
    	
GLAUKOS   CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Thomas W. Burns
    

 

6

 

EXHIBIT A

 

LIST OF ASSETS

 

Patents (status as of July 10, 2014)

 

	
KMOB
   Ref No.
   DOSE.
    	
 
    	
Title of Invention
    	
 
    	
Status
    	
 
    	
Patent
   No.
    	
 
    	
Issued
    
	
11CP3DV1
    	
 
    	
DRUG   ELUTING OCULAR IMPLANT WITH ANCHOR AND METHODS THEREOF
    	
 
    	
Issued
    	
 
    	
8,118,768
    	
 
    	
21-Feb-2012
    
	
001VREP
    	
 
    	
IMPLANT   FOR TREATING OCULAR DISORDERS
    	
 
    	
Issued
    	
 
    	
2078516
    	
 
    	
02-Jan-2013
    
	
11P3D1C1
    	
 
    	
OCULAR   SYSTEM WITH ANCHORING IMPLANT AND THERAPEUTIC AGENT
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
029A
    	
 
    	
ANTERIOR   CHAMBER DRUG-ELUTING OCULAR IMPLANT
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
029PR
    	
 
    	
ANTERIOR   CHAMBER DRUG-ELUTING OCULAR IMPLANT
    	
 
    	
Expired
    	
 
    	
 
    	
 
    	
 
    
	
042PR
    	
 
    	
OCULAR   IMPLANTS CONFIGURED TO STORE AND RELEASE STABLE DRUG FORMULATIONS
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
050PR1
    	
 
    	
IMPLANTS   WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
050PR2
    	
 
    	
IMPLANTS   WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING SAME
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    

 

In regards to the patents and applications included above in the list of the Assets (the “Patents and Applications”), the sale and assignment of such Patents and Applications includes:

 

· the transfer of the right to sue and recover damages for past, present and/or future infringement, the right to injunctive relief and any and all causes of action relating to any of the inventions or discoveries included in such Patents and Applications to the extent of Purchaser’s interest therein; and

 

A-1

 

· all subsequent patents and applications claiming priority to the Patents and Applications, including all patents that may be granted on the Patents and Applications; all provisional applications that the Patents and Applications may claim priority to; all nonprovisional applications claiming priority to the Patents and Applications, including all divisions, continuations, and continuations-in-part, and all Letters Patent of the United States which may be granted thereon and all reissues, reexaminations, supplemental examinations, and extensions thereof; and all rights of priority under International Conventions and any applications for Letters Patent that may hereafter be filed or granted in any country or countries foreign to the United States and all extensions, renewals, and reissues thereof.

 

Trademarks

 

	
Trademark
    	
 
    	
Goods/Services
    	
 
    	
Status
    
	
iDose
    	
 
    	
All   past uses of the trademark, including, but not limited to, Intraocular   drug delivery system comprising of a micro-stent intended for implantation   into the eye for use in the treatment of diseases of the eye; and

 

Surgical   implants comprising intraocular ophthalmic implants, namely micro-stents, for   use in the treatment of diseases of the eye.
    	
 
    	
Common   Law
    
	
iDose TR
    	
 
    	
All   past uses of the trademark, including, but not limited to, Intraocular   drug delivery system comprising of a micro-stent intended for sustained   release of a therapeutic into the eye for use in the treatment of diseases of   the eye; and

 

Surgical   implants comprising intraocular ophthalmic implants, namely micro-stents, for   targeted ophthalmic drug delivery for use in the treatment of diseases of the   eye.
    	
 
    	
Common   Law
    

 

A-2

 

Tangible Assets

 

Front of the Eye Product Assets (G2TR, G3T)

 

	
Description
    	
 
    	
Vendor
    
	
Tablet   press, G3T
    	
 
    	
SMI
    
	
Ultramicro   balance
    	
 
    	
ITIN
    
	
Mold,   G2TR-120 (ceramic)
    	
 
    	
SPT
    
	
Biodot   filler + nozzles
    	
 
    	
Biodot
    
	
Biodot   filler + nozzles, modification
    	
 
    	
Biodot
    
	
Lapping   machine
    	
 
    	
SPT
    
	
O-ring   mold
    	
 
    	
KEF
    
	
2   laminar flow hoods, at Sharp(1), Dose(1)
    	
 
    	
Airtech
    
	
2   laminar flow hoods, at Sharp(1), Dose(1)
    	
 
    	
Airtech
    
	
Differential   micrometer
    	
 
    	
Pacific   Inspection
    
	
Crimping   tool, G2TR
    	
 
    	
SPT
    
	
Crimping   tool, G3T
    	
 
    	
SPT
    
	
Membrane   mold
    	
 
    	
Sertec
    
	
Forming   tool, Cap, G2TR
    	
 
    	
Braxton
    
	
Forming   tool, Cap, G2TR, modification
    	
 
    	
Braxton
    
	
Forming   tool, Cap, G3T, modification
    	
 
    	
Braxton
    

 

Any changes to the foregoing tangible assets in the ordinary course of business (and all replacements, enhancements, improvements, additions, supplies, maintenance parts and the like to the foregoing) to which the parties may agree at the Closing, provided the same relates to the front of the eye products being acquired from DOSE.

 

A-3

 

EXHIBIT B

 

ALLOCATION OF CONSIDERATION

 

The consideration for the Assets shall be allocated among the Assets by mutual agreement of Seller and Purchaser by no later than 180 days after the Closing.

 

 

EXHIBIT C

 

ASSIGNMENT

 

WHEREAS, DOSE Medical Corporation, a Delaware corporation (“ASSIGNOR”) having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 owns all right in the patents and patent applications listed on Schedule 1 to this Assignment (hereafter “the Patents and Patent Applications”);

 

WHEREAS, Glaukos Corporation, a Delaware corporation (“ASSIGNEE”) having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 desires to acquire all right, title, and interest in and to the Patents and Patent Applications;

 

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR does hereby acknowledge that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, ASSIGNOR’s entire right, title, and interest throughout the world in, to, and under the said Patents and Patent Applications, and including:

 

all patents that may be granted on the Patent Applications;

 

all provisional applications that the Patents and Patent Applications may claim priority to;

 

all nonprovisional applications claiming priority to the Patents and Patent Applications, including all divisions, continuations, and continuations-in-part, and all Letters Patent of the United States which may be granted thereon and all reissues, reexaminations, supplemental examinations, and extensions thereof; and

 

all rights of priority under International Conventions and any applications for Letters Patent that may hereafter be filed or granted in any country or countries foreign to the United States and all extensions, renewals, and reissues thereof;

 

ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patents resulting from the Patents and Patent Applications to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment;

 

AND ASSIGNOR DOES HEREBY sell, assign, transfer and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said Patents and Patent Applications before or after issuance;

 

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will communicate to said ASSIGNEE, its successors, legal representatives and assigns, any facts known to ASSIGNOR respecting the Patents and Patent Applications, and testify in any legal

 

 

C - 1

 

proceeding, assist in the preparation of any other Patent Property relating to the Patents and Patent Applications, sign/execute all lawful papers, authorize the filing of and execute and make all rightful oaths and/or declarations in connection with the Patents and Patent Applications, including any patents or patent applications claiming priority thereto, and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the Patents and Patent Applications in all countries.

 

(signature pages follow)

 

C - 2

 

IN TESTIMONY WHEREOF, I hereunto set my hand this        day of                   , 2014.

 

	
 
    	
DOSE   MEDICAL CORPORATION
    
	
 
    	
(“ASSIGNOR”)
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name   Printed:
    	
 
    
	
 
    	
Title:
    	
 
    
				

 

 

State of California }

 

County of                }

 

On                             , before me,                                                                           (here insert name and title of the officer), personally appeared                             , who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

 

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

 

WITNESS my hand and official seal.

 

	
 
    	
 
    	
 
    
	
Notary   Public Signature
    	
 
    	
Notary   Public Seal
    

 

C - 3

 

IN TESTIMONY WHEREOF, I hereunto set my hand this        day of                   , 2014.

 

	
 
    	
GLAUKOS   CORPORATION
    
	
 
    	
(“ASSIGNEE”)
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name   Printed:
    	
 
    
	
 
    	
Title:
    	
 
    
				

 

 

State of California }

 

County of                }

 

On                             , before me,                                                                           (here insert name and title of the officer), personally appeared                             , who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

 

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

 

WITNESS my hand and official seal.

 

	
 
    	
 
    	
 
    
	
Notary   Public Signature
    	
 
    	
Notary   Public Seal
    

 

C - 4

 

EXHIBIT D

 

AMENDED AND RESTATED TRANSITION SERVICES AGREEMENT

 

 

AMENDED AND RESTATED TRANSITION SERVICES AGREEMENT

 

This Amended and Restated Transition Services Agreement (this “Agreement”) is dated as of              , 2014 (the “Effective Date”) by and between Glaukos Corporation, a Delaware corporation (“Glaukos”), and DOSE Medical Corporation, a Delaware corporation (“DOSE”), with reference to the following facts:

 

A.                                    Glaukos and DOSE are parties to that certain Transition Services Agreement, dated as of March 30, 2010, as amended by that certain letter agreement dated July 19, 2012 (the “Original Agreement”) pursuant to which Glaukos provides certain services to DOSE.

 

B.                                    Glaukos and DOSE now wish to amend the Original Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated to read, and the parties hereto agree, as follows:

 

1.                                      Provision of Services.

 

1.1                               Services Provided.  During the Term, Glaukos hereby agrees to provide to DOSE the services specified on Exhibit A attached hereto (the “Services”), at such times as the parties may mutually agree upon.

 

1.2                               Additional Services.  From time to time, DOSE may find it desirable to request, in addition to the Services set forth on Exhibit A, that certain other services be made available by Glaukos (hereinafter referred to as the “Other Services”).  Glaukos shall, in good faith, discuss such request and negotiate in good faith the terms of providing such Other Services including without limitation any increase in the amount of the monthly Fee payable by DOSE pursuant to Section 2.  The provision, if at all, of any Other Services shall be on the terms and conditions agreed upon in writing between Glaukos and DOSE.  Exhibit A shall be amended from time to time to include any Other Services (and the terms and conditions on which they will be provided) agreed to in writing by DOSE and Glaukos.  For the sake of clarity, any such Other Services agreed to and included on Exhibit A, as amended, shall constitute “Services” hereunder.

 

1.3                               Rent Payable Under Sublease.  Glaukos and DOSE are parties to that certain Sublease, dated October 15, 2012, pursuant to which Glaukos sublets to DOSE a portion of the property leased by Glaukos and commonly known as 26051 Merit Circle, Suites 103, 104 and 105, Laguna Hills, California (the “Sublease”).  Glaukos and DOSE anticipate that following the date hereof, DOSE will only be using a small portion of the space sublet to DOSE pursuant to the Sublease (the “DOSE Space”) and Glaukos and DOSE therefore agree that until such time as DOSE begins to use more of the DOSE Space, DOSE will pay to Glaukos rent in the amount of $1,500 per month, rather than the Rent (as defined in the Sublease) provided for in the Sublease.  At such time, if any, as DOSE elects to use more of the DOSE Space, Glaukos and DOSE shall discuss and negotiate in good faith the amount of rent that will be paid by DOSE based upon the amount of the DOSE Space to be used by DOSE.  The agreement of the parties set forth in this Section 1.3 with respect to the amount of rent to be paid by DOSE, shall not

 

 

affect or modify any of the other terms or provisions of the Sublease, all of which shall remain in full-force and effect.

 

1.4                               Cancellation.  DOSE may cancel any Service that it is receiving from Glaukos by providing at least ten (10) days prior Notice to Glaukos of its decision to cancel such Service.  Upon any such cancellation, the parties shall negotiate in good faith whether to reduce the amount of the monthly Fee payable by DOSE pursuant to Section 2 in light of such cancelled Services.

 

2.                                      Fee.  In consideration of the Services, DOSE shall pay to Glaukos a monthly fee of $4,500.00 no later than ten (10) days after the end of each month in which Glaukos provided any Services under this Agreement.

 

3.                                      Term and Termination.  The term of this Agreement shall be for the period commencing on the Effective Date and continuing through and including                          ,          (the “Term”); provided, however, that this Agreement may be earlier terminated (a) by DOSE upon not less than sixty (60) days’ prior written notice to Glaukos, (b) by Glaukos upon not less than one hundred eighty (180) days’ prior written notice to DOSE or (c) by mutual agreement of Glaukos and DOSE.  Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination.

 

4.                                      Direction of Employees; No Agency.  Notwithstanding anything herein to the contrary, Glaukos’ employees providing Services hereunder shall at all times be and remain employees of Glaukos in their performance of Services.  Glaukos shall be responsible for directing and supervising the activities of such employees in their performance of the Services, subject to the directions of DOSE to Glaukos which such directions to be consistent with the terms of this Agreement.  Glaukos shall be solely responsible for the payment of all wages, bonuses, commissions, benefits and any other direct or indirect compensation for their personnel, including those personnel involved in the delivery of the Services, as well as be responsible for their insurance costs and expenses.  This Agreement shall not create a joint venture, partnership, employment, or agency relationship between Glaukos and DOSE, nor shall any party hereto (and its respective affiliates) have the authority to bind any other party hereto in any respect, except as otherwise provided herein.  In its provisions of the Services hereunder, Glaukos shall act under this Agreement solely as an independent contractor and not as an agent of DOSE.

 

5.                                      No Representations or Warranties.  All Services will be provided by Glaukos “as is” with no warranties or representations of any kind whatsoever, express or implied, whether arising under law, equity, custom, usage or otherwise, including without limitation any implied warranties of merchantability and any warranty that the Services are fit for any particular purpose.

 

6.                                      Indemnification.  DOSE hereby agrees to indemnify and hold Glaukos and its directors, officers, employees, Affiliates, stockholders, agents and assigns harmless from and against any and all claims, losses, damages, liabilities, deficiencies, obligations or out-of-pocket expenses and costs and expenses of investigation, arising out of or resulting from Glaukos’ performance or nonperformance of the Services hereunder except for gross negligence or willful misconduct of Glaukos.

 

2

 

7.                                      Confidentiality.

 

7.1                               Use of Confidential Information.  From time to time prior to the commencement of and during the Term, each party hereto has disclosed or may disclose its confidential information (e.g., information regarding a disclosing party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results, contractual relationships, etc.) to the other party.  In addition each party may, from time to time during the Term, obtain or have access to the other party’s confidential information.  As used herein, the term “confidential information” does not include information that (i) is in or comes into the public domain through no fault of the receiving party or any of its affiliates or their representatives, or (ii) is lawfully acquired without confidentiality obligations to the disclosing party from sources having the right to make such disclosure or (iii) was developed independently by the receiving party without use of any confidential information of the disclosing party.  Each party shall maintain (and cause its affiliates and subcontractors to maintain) the confidentiality of the other party’s confidential information and not to use or disclose such confidential information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any confidential information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the confidential information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s confidential information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.

 

7.2                               Return of Confidential Information.  Upon termination of this Agreement, unless a party has a continuing right to use such confidential information pursuant to a license granted hereunder, upon request of the other party, each of the parties hereto agrees to return to the other all such confidential information of the other, or, at its option destroy such confidential information and, thereafter, certify immediately to the disclosing party that all such confidential information has been returned or destroyed.

 

8.                                      Ownership of New Technology.

 

8.1  New Technology.

 

(a)                                 Except as provided in Section 8.2 below, any and all (i) inventions (whether or not reduced to practice and whether or not patentable), (ii) works of authorship, (iii) trade secrets, know-how, confidential information (including but not limited to confidential ideas, research and development, technology, discoveries, methods, formulas, compositions, manufacturing processes, designs, specifications, clinical trial protocols, statistical analyses and

 

3

 

other regulatory information, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals) and all other proprietary information and data (including but not limited to technical and safety, efficacy and other clinical data) conceived, developed or reduced to practice by Glaukos or DOSE, either jointly or individually, in whole or in part, after the date hereof and during the Term (collectively, “New Technology”) shall be owned by (i) DOSE to the extent such New Technology is within the Dose Field of Use as defined in the Amended and Restated Patent License Agreement dated                , 2014, between Glaukos and DOSE (the “Glaukos/DOSE License Agreement”) and (ii) Glaukos to the extent such New Technology is outside the Dose Field of Use.

 

(b)                                 Each party shall disclose to the other party any New Technology promptly after it has been conceived, developed or reduced to practice.  For purposes of this Section 8, all determinations of inventorship shall be made in accordance with United States patent law.  For no additional consideration, each party (the “Assignor”) hereby assigns to the applicable other party (the “Assignee”) all of the Assignor’s right, title and interest, worldwide, in and to any New Technology (including without limitation all intellectual property rights associated therewith and all copies and tangible embodiments thereof, in whatever form or medium) consistent with the ownership allocation described above so that sole and exclusive ownership therein resides in DOSE to the extent such New Technology is within the Dose Field of Use and in Glaukos to the extent such New Technology is outside the Dose Field of Use.  Each applicable Assignor shall, at the applicable Assignee’s request and expense, execute documents and perform such acts as such Assignee may deem necessary, to confirm in such Assignee, all right, title and interest throughout the world, in and to any New Technology consistent with the ownership allocation set forth herein (including all patents, trademarks copyrights and other applicable statutory protections thereon), and to enable and assist Assignee in procuring, maintaining, enforcing and defending patents, trademarks, copyrights and other statutory protections throughout the world in and to any such New Technology.  Each party shall cause each of its employees, contractors and consultants to execute and deliver an agreement assigning all of their respective right, title and interest in and to any New Technology consistent with the above ownership allocation so that sole and exclusive ownership therein resides in DOSE to the extent such New Technology is within the Dose Field of Use and in Glaukos to the extent such New Technology is outside the Dose Field of Use.

 

8.2                               Exceptions.  Notwithstanding Section 8.1:

 

(a)                                 By way of clarification and for the avoidance of doubt, the term “New Technology” shall not include any invention that is the subject of any patent or patent application included within the definitions of “Dose Licensed Patents”, “Glaukos Group 1 Licensed Patents” or “Glaukos Group 2 Licensed Patents” as such terms are defined in the Glaukos/Dose License Agreement.

 

(b)                                 Any New Technology to the extent it relates to (i) a delivery device for a Glaukos product (irrespective of whether such delivery device can also be used or modified to deliver a DOSE product); (ii) a visualization device or method (e.g., for targeted placement of an implant); (iii) an introducer or corneal penetration device (whether apart from or part of a delivery device); or (iv) a device or method for accessing in an ab interno manner the suprachoroidal space or the supraciliary space (for example, an integrated spatula or a method of

 

4

 

“teasing of ciliary”) shall be owned by the party conceiving, developing or reducing to practice such New Technology, provided that, the party owning such New Technology hereby grants to the other parties a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use such New Technology (including without limitation the right to copy and create derivative works) to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Glaukos Field of Use if such other party is Glaukos and within the Dose Field of Use if such other party is DOSE.

 

9.                                      Miscellaneous.

 

9.1                               Binding Effect.  This Agreement will be binding upon, and inure to the benefit of, the parties and their respective successors and assigns.

 

9.2                               Captions.  Section titles, captions and headings contained herein are inserted as a matter of convenience and are for reference only and they do not define, limit, extend or describe the scope of this Agreement or any provision hereof.

 

9.3                               Notices.  All notices, requests, demands, claims and other communications hereunder (“Notices”) shall be in writing.  Any Notice hereunder shall be deemed duly given (i) upon receipt if delivered in person; (ii) on the date delivered by Federal Express, UPS, DHL or similar international courier service as established by the sender by evidence obtained from the courier; (iii) upon transmission by facsimile, provided an electronic acknowledgement of receipt is generated; or (iv) on the fifth day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid; in each case addressed to the intended recipient as set forth below (or to such other address or facsimile number as the intended recipient may request by way of an appropriate Notice given in accordance with this Section):

 

	
If to DOSE:

 

DOSE Medical Corporation

26051 Merit Circle, Suite 105

Laguna Hills, CA 92653

Facsimile No.: 949-367-9984
    	
If to Glaukos:

 

Glaukos Corporation

26051 Merit Circle, Suite 103

Laguna Hills, CA 92653

Facsimile No.: 949-367-9984
    

 

9.4                               Waiver.  The waiver by either party of any breach by the other party of any of the representations, warranties, promises and/or covenants contained herein shall not prevent the subsequent enforcement of any such representation, warranty, promise and/or covenant as to any aspect which has not been waived, nor shall it be deemed a waiver of any subsequent breach thereof.  No waiver of any breach or violation hereof shall be implied from forbearance or failure by a party to take action thereon.

 

9.5                               Assignment.  Neither party shall assign this Agreement or any right, interest or benefit under this Agreement, nor delegate any of its duties or obligations hereunder, without the prior written consent of the other party.  Except as permitted by the foregoing, any attempted assignment or delegation shall be null, void, and of no effect.  Subject to the

 

5

 

foregoing, this Agreement shall be binding upon and inure to the benefit of the successors and assigns of each of the parties.

 

9.6                               Entire Agreement.  This Agreement, including the exhibits attached hereto, constitutes the entire agreement between the parties hereto regarding the subject matter hereof and no terms, conditions or provisions other than those expressly contained herein shall be deemed to be part of this Agreement.  This Agreement supersedes any prior agreements (oral or written) between the parties. The exhibits identified in this Agreement are incorporated herein by reference and made a part hereof.

 

9.7                               Amendments.  Neither this Agreement nor any of the terms or conditions hereof may be waived, amended or modified except by means of a written instrument duly executed by both parties.

 

9.8                               Attorneys’ Fees.  In any action to enforce this Agreement, the prevailing party shall be awarded all court costs and reasonable attorneys’ fees incurred, including such costs and attorneys’ fees incurred in enforcing and collecting any judgment.

 

9.9                               Cumulative Remedies.  The remedies set forth in this Agreement are cumulative and shall be in addition to any and all other remedies available at law or in equity.

 

9.10                        Further Assurances.  The parties, without further consideration of any kind, shall each execute and deliver, or cause to be executed and delivered, such other instruments, and take, or cause to be taken, such other action, as shall reasonably be requested by the other party hereto to more effectively carry out the terms and provisions of this Agreement.

 

9.11                        Severability.  Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.

 

9.12                        Survival.  The provisions of Sections 4, 6, 7, 8 and 9 shall survive the termination of this Agreement.

 

9.13                        Counterparts.  This Agreement may be executed in any number of counterparts which together shall constitute one and the same instrument.  Delivery of an executed counterpart of a signature page by facsimile shall be effective as delivery of a manually executed counterpart.

 

9.14                        Governing Law.  This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

 

[SIGNATURE PAGE FOLLOWS]

 

6

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their authorized representatives as of the day and year first above written.

 

	
 
    	
GLAUKOS   CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Its:
    	
 
    
	
 
    	
 
    
	
 
    	
DOSE   MEDICAL CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Its:
    	
 
    

 

7

 

EXHIBIT A

 

Services

 

1.                                      Accounting and Financial Services

 

·                  General ledger accounting services, including but not limited to:

·                  bookkeeping

·                  month-end closing

·                  Cash management

·                  Accounts payable management and bill paying

·                  Payroll services

 

2.                                      IT Support

 

3.                                      Limited Engineering Support

 

 

EXHIBIT E

 

AMENDED AND RESTATED PATENT LICENSE AGREEMENT

 

 

AMENDED AND RESTATED 
 PATENT LICENSE AGREEMENT

 

THIS AMENDED AND RESTATED PATENT LICENSE AGREEMENT (“Amended and Restated Agreement”) is entered into and effective as of this          day of         , 2014 (the “Restatement Date”), by and between GLAUKOS CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“GLAUKOS”), and DOSE MEDICAL CORPORATION, a Delaware corporation, having a place of business at 26051 Merit Circle, Suite 103, Laguna Hills, California 92653 (“DOSE”).

 

RECITALS

 

A.                                    GLAUKOS and DOSE have entered into that certain Patent License Agreement dated March 30, 2010, as amended by that certain letter agreement dated July 19, 2012 (the “Original Agreement”) under which, among other things, each party has licensed the other party certain rights to certain patent and patent applications; and

 

B.                                    GLAUKOS and DOSE now wish to amend and restate the Original Agreement as set forth herein.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Original Agreement is hereby amended and restated to read, and the parties hereto agree, as follows:

 

1.                                      DEFINITIONS

 

For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

1.1.                            “Agreement” means the Original Agreement as amended and restated by this Amended and Restated Agreement, as hereafter amended from time to time in accordance with its terms.

 

1.2.                            “Biosensor” means any system and/or apparatus designed (i) to be implanted in or affixed to the human body (or any part thereof) and (ii) to monitor and/or measure at least one state or condition of the human body (or any part thereof) or any changes or other aspects affecting the human body (or any part thereof).

 

1.3.                            “Confidential Information” means any information that in any way relates to a party, including without limitation information regarding a party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results and contractual relationships; provided, however, that the term “Confidential Information” shall not include information: (i) that, at the time of disclosure, is generally available to the public; (ii) that, after disclosure hereunder, becomes generally available to the public, except as a result of a breach of this Agreement by the recipient of 

 

1

 

such information; (iii) that becomes available to the recipient of such information from a third party that is not legally or contractually prohibited by the disclosing party from disclosing such information; or (iv) that the recipient can demonstrate was developed by or for such recipient without the use of any of the Confidential Information of the disclosing party hereunder.

 

1.4.                            “Dose Field of Use” means (i) any and all applications of a Biosensor and/or (ii) any and all applications for the treatment of any disorder or disease (other than Glaucoma) primarily affecting the posterior segment of the eye (i.e. the back two-thirds of the eye that includes the anterior hyaloid membrane and all of the optical structures behind it: the vitreous humor, retina, choroid, and optic nerve), provided that such applications described in this clause (ii) do not include an apparatus that includes a drainage lumen unless the drainage lumen’s primary purpose is to relieve intraocular pressure caused by the administration of steroids, delivered by an apparatus implanted in or on the eye, to treat a disorder or disease primarily affecting the posterior segment of the eye and not associated with Glaucoma.

 

1.5.                            “Dose Licensed Patents” means any and all patents and patent applications listed in Exhibit A to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit A, including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Dose Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit A.

 

1.6.                            “Effective Date” means March 30, 2010.

 

1.7.                            “Glaukos Field of Use” means any and all applications for the treatment of (i) Glaucoma, including but not limited to therapies directed toward reducing intraocular pressure and/or reducing the death of retinal ganglion cells (i.e., neuroprotection) associated with Glaucoma) and/or (ii) any disorder or disease primarily affecting the anterior segment of the eye (i.e., the front third of the eye that includes the structures in front of the vitreous humor: the cornea, iris, ciliary body, the lens, the anterior chamber between the posterior surface of the cornea and the iris and the posterior chamber between the iris and the front face of the vitreous); provided that, such applications described in clauses (i) or (ii) above do not include a Biosensor.

 

1.8.                            “Glaukos Group 1 Licensed Patents” means any and all patents and patent applications listed in Exhibit B to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit B, including, but not limited to, all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 1 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit B.

 

2

 

1.9.                            “Glaukos Group 2 Licensed Patents” means any and all patents and patent applications listed in Exhibit C to this Agreement and any and all U.S. and foreign patents and patent applications, as of the Restatement Date or thereafter, that claim priority to one or more of the patents and patent applications listed in Exhibit C, including, but not limited to all reissues, reexaminations, continuations, continuations-in-part and divisionals of such patents and patent applications; provided, however, that for such continuations-in-part (and foreign counterparts to such continuations-in-part), Glaukos Group 2 Licensed Patents only include those claims in the continuations-in-part (and claims in any foreign counterparts to such continuations-in-part) that are entitled to priority to one or more of the patents and patent applications listed in Exhibit C.

 

1.10.                     “Regulatory Information” means pre-clinical, clinical, manufacturing and testing data, protocols, and chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, safety, efficacy, bioequivalency, quality assurance, quality control and other information and data relating to any investigations, trials and/or the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for any product, including but not limited to, with respect to GLAUKOS, information relating to preliminary investigations and the preparation, submission and prosecution of one or more applications filed in connection with obtaining regulatory approval for the iStent® (a/k/a G1 device), iStent InjectTM (a/k/a G2 device), and iStent SupraTM (a/k/a G3 device) including but not limited to FDA application materials, safety and efficacy data, clinical trial protocols and reports, statistical analyses, communications with the FDA, etc.

 

1.11.                     “Term of Access” means the period commencing on the Effective Date and continuing through and including                          ,         ; provided, however, that the end date of the Term of Access may be earlier as determined (i) by DOSE upon not less than sixty (60) days’ prior written notice to GLAUKOS, (ii) by GLAUKOS upon not less than one hundred eighty (180) days’ prior written notice to DOSE or (c) by mutual agreement of GLAUKOS and DOSE.

 

1.12.                     “Valid Claim” means a claim that (i) in the case of any issued and unexpired patent, has not been dedicated to the public, disclaimed, nor held invalid or unenforceable by a court or other government entity of competent jurisdiction in an unappealed or unappealable decision, or (ii) in the case of any patent application, (a) has not been cancelled, withdrawn or abandoned, without being refiled in another application, in the applicable jurisdiction, (b) shall not have been finally rejected by a governmental entity or other governmental action from which no appeal can be taken and (c) shall not have been pending for more than five (5) years in the United States Patent and Trademark Office or seven (7) years in a foreign patent office.  For purposes of this definition, the time period for which a claim is pending shall begin on the priority date for such claim, and shall continue until such claim is either issued or is no longer deemed to be a Valid Claim in accordance with the preceding sentence regardless of whether such claim is amended or refiled in another application in the applicable jurisdiction.  If a claim of a patent application which ceased to be a Valid Claim under clause (ii) of the preceding sentence due to the passage of time later issues as part of a patent described within clause (i) of the preceding sentence then it shall again be considered to be a Valid Claim effective as of the issuance of such patent

 

3

 

2.                                      EXCLUSIVE LICENSE FROM DOSE TO GLAUKOS

 

2.1.                            Subject to Section 2.2, DOSE hereby grants to GLAUKOS a limited, exclusive (even as to DOSE), irrevocable, perpetual, fully paid-up, worldwide license under the Dose Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all methods, solely in the Glaukos Field of Use.  The license granted to GLAUKOS under this Section 2.1, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Dose Licensed Patents within the Dose Field of Use.  The license granted to GLAUKOS under this Section 2.1 includes the right to sublicense, provided that any such sublicense from GLAUKOS be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 2.2.

 

2.2.                            Neither GLAUKOS nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 2.1 above) infringe a Valid Claim of a Dose Licensed Patent; provided that, the foregoing of this Section 2.2 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

3.                                      EXCLUSIVE LICENSE FROM GLAUKOS TO DOSE

 

3.1.                            Subject to Section 3.2, GLAUKOS hereby grants to DOSE a limited, exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license under the Glaukos Group 1 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Dose Field of Use.  The license granted to DOSE under this Section 3.1, however, shall not limit GLAUKOS’ right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 1 Licensed Patents within the Glaukos Field of Use.  The license granted to DOSE under this Section 3.1 includes the right to sublicense, provided that any such sublicense from DOSE be restricted to the Dose Field of Use and subject to the terms of this Agreement, including without limitation Section 3.2.

 

3.2.                            Neither DOSE nor its sublicensees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the anterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 3.1 above) infringe a Valid Claim of a Glaukos Group 1 Licensed Patent; provided that, the foregoing of this Section 3.2 shall not limit DOSE from seeking or obtaining any label indication for application(s) of a Biosensor.

 

4

 

4.                                      EXCLUSIVE LICENSE TO DOSE / LICENSE BACK TO GLAUKOS

 

4.1.                            GLAUKOS hereby grants to DOSE an exclusive (even as to GLAUKOS), irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of one or more claims of the Glaukos Group 2 Licensed Patents.

 

4.2.                            Subject to Section 4.3, DOSE hereby grants back to GLAUKOS a limited exclusive (even as to DOSE), irrevocable, fully paid-up, perpetual, worldwide sublicense, with the right to sublicense such sublicense rights, under the Glaukos Group 2 Licensed Patents to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods solely in the Glaukos Field of Use.  The sublicense to GLAUKOS, however, shall not limit DOSE’s right to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any all products and to practice any and all methods under the Glaukos Group 2 Licensed Patents within the Dose Field of Use.  This sublicense includes the right for GLAUKOS to grant further sublicenses, provided that any such further sublicense be restricted to the Glaukos Field of Use and subject to the terms of this Agreement, including without limitation Section 4.3.

 

4.3.                            Neither GLAUKOS nor its sublicencees shall seek or obtain a label indication in any country for the treatment of any disorder or disease affecting the posterior segment of the eye for any product whose manufacture, use, offer for sale, sale or importation in or to such country would (absent the license granted under Section 4.2 above) infringe a Valid Claim of a Glaukos Group 2 Licensed Patent; provided that, the foregoing of this Section 4.3 shall not limit GLAUKOS from seeking or obtaining any label indication for the treatment of Glaucoma or reduction of intraocular pressure and/or reduction of the death of retinal ganglion cells (i.e., neuroprotection).

 

5.                                      ASSIGNMENT OF RIGHTS

 

5.1.                            Each of GLAUKOS and DOSE shall have the right to assign in whole or in part its rights, obligations and licenses under this Agreement.

 

5.2.                            Each party shall have the right to assign any or all of its patents or other intellectual property licensed to the other party by this Agreement only if such assignment is expressly subject to the continuance of such license.

 

6.                                      REGULATORY APPROVAL; TECHNOLOGY LICENSE

 

6.1.                            Each party shall be solely responsible, at its sole cost and expenses, for identifying and obtaining, including testing or other procedures, any necessary regulatory or safety approvals or certifications (e.g., FDA and safety agencies) required for the marketing and sale by such party of its products in any country.  Nevertheless, each party will cooperate with the other party by providing, upon request, any Regulatory Information in its possession and control that could reasonably assist the other party to obtain approvals or certifications of its 

 

5

 

products.  Each party will further permit the other party and its sublicensees to expressly reference each party’s Regulatory Information in the other party’s filings to obtain such approvals or certifications of its products.

 

6.2.                            Each party acknowledges and agrees that Regulatory Information provided by the other party may contain Confidential Information belonging to the other party. Each party shall disclose its Confidential Information to the other party only on a confidential basis subject to the provisions of Section 13.9.  Any use or disclosure of the Confidential Information of a party under this Agreement, including but not limited to any reference by the other party to the Confidential Information of a party in the other party’s filings to obtain approvals or certifications, shall be designated as confidential.

 

6.3.                            GLAUKOS hereby grants to DOSE a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of GLAUKOS (including but not limited to Regulatory Information and Confidential Information of GLAUKOS), existing as of the Effective Date or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Dose Field of Use.  From time to time (including without limitation after the Term of Access), upon DOSE’s written request and expense, GLAUKOS shall promptly deliver to DOSE copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in Glaukos’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.4.                            DOSE hereby grants to GLAUKOS a non-exclusive, irrevocable, perpetual, fully paid-up, worldwide license, with the right to sublicense, to use (including without limitation the right to copy and create derivative works) any and all works of authorship, know-how, trade secrets, and other proprietary data or information of DOSE (including but not limited to Regulatory Information and Confidential Information of DOSE), existing as the Effective Date and/or during the Term of Access, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products, and to practice any and all inventions, within the Glaukos Field of Use.  From time to time (including without limitation after the Term of Access), upon GLAUKOS’s written request and expense, DOSE shall promptly deliver to GLAUKOS copies of any and all records, documentation and other tangible embodiments (in whatever form or medium) in DOSE’s possession or control embodying any works of authorship, know-how, trade secrets or other proprietary data or information within the scope of the license rights granted above.

 

6.5.                            Notwithstanding anything herein to the contrary, the rights and obligations of each party set forth Sections 6.1, 6.2, 6.3 and 6.4 shall not pertain to any data or other information arising from investigations or clinical trials conducted after the Term of Access but shall continue to pertain to all other Regulatory Information, including but not limited to any regulatory applications filed after the Term of Access to the extent based on data or information existing as of the Effective Date and/or during the Term of Access.

 

6

 

7.                                      OWNERSHIP

 

7.1.                            DOSE acknowledges that GLAUKOS is the sole owner of the Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents, and DOSE agrees that it does not obtain any interest in such patents except for the rights granted herein.  DOSE agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by GLAUKOS of such patents, or GLAUKOS’ intellectual property rights therein.  Furthermore, DOSE agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of such patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of such patents, to the extent and in jurisdictions where permitted by law.

 

7.2.                            GLAUKOS acknowledges that DOSE is the sole owner of the Dose Licensed Patents, and GLAUKOS agrees that it does not obtain any interest in such patents except for the rights granted herein.  GLAUKOS agrees not to take any action challenging or opposing, on any grounds whatsoever, the ownership by DOSE of the Dose Licensed Patents, or DOSE’s intellectual property rights therein.  Furthermore, GLAUKOS agrees not to contest the validity or enforceability, or to assist or request any third party to contest the validity or enforceability of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law, in any judicial, governmental, or quasi-governmental suit or proceeding; and not to request reexamination, post grant review, or inter partes review, or assist or request any third party to request reexamination, post grant review, or inter partes review of any of the Dose Licensed Patents, to the extent and in jurisdictions where permitted by law.

 

7.3.                            DOSE, in its sole discretion and at its own expense, shall control the entire patent process relating to the Dose Licensed Patents and the Glaukos Group 2 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that DOSE agrees to (i) promptly provide copies of all prosecution documents to GLAUKOS upon request; (ii) provide GLAUKOS an opportunity to contribute to the prosecution of claims relating to the Glaukos Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to GLAUKOS, including paying any and all maintenance fees and annuities; and (iv) notify GLAUKOS in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to GLAUKOS, and if requested by GLAUKOS, assign such patent or application to GLAUKOS to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.3 shall hereby be licensed back to the DOSE on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Glaukos Field of Use.  With respect to the Glaukos Group 2 Licensed Patents, GLAUKOS will, among other things, assist DOSE in exercising its rights hereunder to 

 

7

 

control the entire patent process related to the Glaukos Group 2 Patents, and GLAUKOS hereby irrevocably designates and appoints DOSE as its agent and attorneys-in-fact, coupled with an interest, to act for and on GLAUKOS’ behalf to execute and file any document and to do all other lawfully permitted acts to further the foregoing provisions of this Section 7.3 with the same legal force and effect as if executed by GLAUKOS.

 

7.4.                            GLAUKOS, in its sole discretion and at its own expense, shall control the entire patent process relating to the Glaukos Group 1 Licensed Patents, including without limitation, prosecution of patent applications and maintenance, reexamination, reissue, and extension of patents; provided, however, that GLAUKOS agrees to (i) promptly provide copies of all prosecution documents to DOSE upon request; (ii) provide DOSE an opportunity to contribute to the prosecution of claims relating to the Dose Field of Use, including without limitation making suggestions for (A) claims to pursue, (B) claim amendments and (C) responsive arguments, and consider in good faith whether to adopt any such suggestions and contributions in any responsive filing to a patent office; (iii) subject to clause (iv) below, maintain all issued patents and pending patent applications licensed to DOSE, including paying any and all maintenance fees and annuities; and (iv) notify DOSE in writing sixty (60) days prior to the abandonment of any patent or application for a patent licensed to DOSE, and if requested by DOSE, assign such patent or application to DOSE to take action to prevent the abandonment thereof.  Any patent or patent application assigned pursuant to this Section 7.4 shall hereby be licensed back to GLAUKOS on a non-exclusive, worldwide, irrevocable, perpetual, fully paid-up basis, without the right to sublicense, to make, have made, use, import, offer for sale, sell and otherwise develop and commercialize any and all products and to practice any and all methods that fall within the scope of such patent or patent application outside of the Dose Field of Use.

 

8.                                      TERM

 

8.1.                            This Agreement shall remain in effect until the expiration date of the last expiring of the Dose Licensed Patents, Glaukos Group 1 Licensed Patents and Glaukos Group 2 Licensed Patents.

 

8.2.                            Notwithstanding the foregoing, Sections 1, 5, 6, 8.2, 11, 12 and 13 shall survive any expiration of this Agreement.

 

9.                                      ENFORCEMENT OF PATENTS

 

9.1.                            Each party agrees that if it becomes aware of any infringement of any of the rights belonging to the other party that are subject of this Agreement, it will promptly disclose such information to the other party.

 

9.2.                            Subject to Sections 9.3 and 9.4, each party shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend any patents owned by such party against any infringer.

 

9.3.                            GLAUKOS shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the 

 

8

 

Dose Licensed Patents and the Glaukos Group 2 Licensed Patents solely in the Glaukos Field of Use.

 

9.4.                            DOSE shall have the sole and exclusive right, but not the obligation, to bring, prosecute and control any action or proceeding, at its expense, to enforce or defend the Glaukos Group 1 Licensed Patents in the DOSE Field of USE and the Glaukos Group 2 Licensed Patents in any and all applications other than the Glaukos Field of Use.

 

9.5.                            In the event of any action or proceeding under this Section 9, each party agrees to reasonably cooperate with the party taking such action and, at the request of the party taking such action, to give such party all needed information and assistance to file and prosecute such action or proceeding; provided that the acting party shall promptly reimburse the assisting party for all verified out-of-pocket expenses incurred in providing such assistance.  In connection with the foregoing, with respect to any legal action brought under Sections 9.3 or 9.4, each party agrees to join in such action (as necessary to provide standing for such action based on such party’s ownership of the patents at issue) as a party plaintiff if requested to do so by the other party taking such action at such other party’s expense.

 

9.6.                            In resolving any action or proceeding brought by DOSE or GLAUKOS under Sections 9.3 or 9.4, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is outside the scope of such acting party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to any claim contained therein (provided this clause (ii) shall not apply to DOSE’s enforcement or defense of the Glaukos Group 2 Licensed Patents with respect to claims outside the Glaukos Field of Use); (iii) settles any claim as to any patent rights exclusively licensed to the other party hereunder or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.3 or 9.4, respectively, shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

9.7.                            If DOSE with respect to the Dose Licensed Patents or the Glaukos Group 2 Licensed Patents or GLAUKOS with respect to the Glaukos Group 1 Licensed Patents desires to participate in an action brought by the other party under Sections 9.3 or 9.4, respectively, it shall have the right to do so at its own expense; provided such participation is limited to protecting its patent rights licensed hereunder or owned by it (subject to the exclusive licenses granted herein).  The party taking legal action under Sections 9.3 or 9.4 shall consider in good faith any and all concerns or comments by DOSE or GLAUKOS (as the case may be) in exercising its rights under the foregoing sentence.

 

9.8.                            In resolving any action or proceeding brought by DOSE or GLAUKOS under Section 9.2, the acting party shall not settle any claim or enter into any other voluntary disposition of the action or proceeding that (i) admits that any third party product, which is 

 

9

 

within the scope of the other party’s exclusive license rights hereunder, does not infringe an asserted patent; (ii) admits that any asserted patent is invalid or unenforceable as to claims within the other party’s exclusive license rights hereunder; (iii) settles any claim as to any patent rights exclusively licensed to the other party: or (iv) would require the other party to be subject to an injunction or to make a monetary payment or would otherwise adversely affect the other party’s rights hereunder, in each case of clauses (i), (ii), (iii) and (iv) above, without the other party’s prior written consent.  Any and all damages, settlement amounts or other consideration obtained by a party to the extent arising as a result of its enforcement or defense of its patent rights pursuant to Sections 9.2 shall go to such party after reimbursement of any expenses respectively incurred by the parties in accordance with this Section 9 in connection with such enforcement or defense.

 

10.                               PATENT MARKING

 

Each party agrees to mark, and to require its licensees or sublicensees to mark, each product that is made, used, sold or imported pursuant to the provisions herein with a patent notice in compliance with the applicable statutory requirements.

 

11.                               NO REPRESENTATIONS AND WARRANTIES

 

11.1.                     EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES WHATSOEVER TO THE OTHER PARTY UNDER THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ALL SUCH WARRANTIES ARE HEREBY EXPRESSLY EXCLUDED AND DISCLAIMED TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW.

 

11.2.                     Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by GLAUKOS to DOSE as to the scope or validity of the Glaukos Group 1 Licensed Patents or Glaukos Group 2 Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

11.3.                     Without limiting Section 11.1, nothing in this Agreement shall be construed as a warranty or representation by DOSE to GLAUKOS as to the scope or validity of the Dose Licensed Patents, or that anything made, used, sold or otherwise disposed of under the rights granted in this Agreement is or will be free from infringement of patents of third parties.

 

12.                               NOTICES

 

12.1.                     In the event that either GLAUKOS or DOSE sublicenses or assigns any of the rights, obligations or licenses provided under this Agreement or assigns any of the patents licensed hereunder, the assigning or sublicensing party must promptly notify the other party and must identify the third party to whom such assignment or sublicense has been made, including providing a name and contact information of a representative of such third party and a reasonable description of the rights so sublicensed or assigned and/or a list of the patents so assigned.

 

10

 

12.2.                     Any notice, request, demand, or other communication required or permitted to be given under this Agreement shall be in writing and addressed to its addressee at the address set forth above, or such address as a party may specify from time to time.

 

12.3.                     Such notice, request, demand, or other communication shall be deemed to have been duly given (i) at the time of delivery when hand delivered to the other party; or (ii) at the time of confirmed transmission when sent by facsimile at the address and number set forth below, provided that a confirmation copy is sent by overnight or registered or certified mail within twenty-four (24) hours after the fax transmission (any notice given by facsimile shall be deemed received on the next business day if such notice is received after 5:00 p.m. (recipient’s time) or on a non-business day); or (iii) at the time of delivery, or of attempted delivery in the event that delivery cannot be completed due to no fault of the sender, when sent by registered or certified mail or by overnight courier service.

 

13.                               GENERAL PROVISIONS

 

13.1.                     The parties hereby agree that no agency, joint venture or partnership is created by this Agreement, and that neither party shall incur obligations in the name of the other party, except as expressly set forth in this Agreement.

 

13.2.                     This Agreement shall be governed and construed in accordance with the laws of the State of California, and the parties agree that it is executed and delivered in that state.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the parties agree that such action shall be brought in the United States District Court for the Central District of California, or in the State Court for the County of Orange, California, and the parties hereby submit to the exclusive jurisdiction of said Courts.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled, in addition to its court costs or arbitration fees, to such reasonable attorneys’ fees, expert witness fees, and other litigation expenses as shall be fixed by a court of competent jurisdiction.

 

13.3.                     If any provision of this Agreement should be held to be void or unenforceable, in whole or in part, the court or tribunal so holding shall reform the provision to make it enforceable while maintaining the spirit and goal of the provision, and if the court or tribunal finds it cannot so reform that provision, such provision or part thereof shall be treated as severable, leaving valid the remainder of this Agreement.

 

13.4.                     This Agreement, including its exhibits and all documents referenced herein, constitutes the entire understanding and agreement of the parties as to the subject matter herein, and there are no representations, warranties, promises, or undertakings other than those contained herein.  As to the subject matter hereof, this Agreement supersedes and cancels all previous agreements between the parties hereto.  No course of conduct or dealing between the parties shall act as a modification or waiver of any provision of this Agreement, and no waiver or modification of any of the terms or provisions of this Agreement, or failure or delay on the part of either party hereto in insisting upon or enforcing or resorting to any of its powers, rights, remedies, or options hereunder, and no partial or single exercise thereof, shall constitute a waiver 

 

11

 

of any such powers, rights, remedies or options, unless such waiver be in writing and signed by the party to be charged.

 

13.5.                     This Agreement shall be binding upon the parties hereto and their respective subsidiaries, affiliates, heirs, legal representatives, successors and permitted assigns.

 

13.6.                     The terms of this Agreement have been negotiated by the parties hereto and the language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent.  This Agreement shall be construed without regard to any presumption or rule requiring construction against the party causing such instrument or any portion thereof to be drafted, or in favor of the party receiving a particular benefit under the Agreement.  No rule of construction will be applied against any party.

 

13.7.                     The headings in this Agreement are intended for convenience only, and shall not be used to interpret the meaning of this Agreement or to determine the rights of the parties.

 

13.8.                     The parties agree that they shall, at any time and from time to time, on the written request of either party, execute and deliver promptly, at the requesting parties’ expense, all such further documents and instruments and shall do or procure to be done, all such further acts and things as may, from time to time, reasonably be required for the purpose of giving full effect to the provisions of this Agreement.

 

13.9.                     From time to time prior to the Effective Date and thereafter, each party hereto has disclosed or may disclose its Confidential Information to the other party.  In addition each party may, from time to time, obtain or have access to the other party’s Confidential Information.  Each party shall maintain (and cause its employees and contractors to maintain) the confidentiality of the other party’s Confidential Information and not to use or disclose such Confidential Information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any Confidential Information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the Confidential Information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s Confidential Information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.  Upon request of the disclosing party, unless the receiving party has a continuing right to use such Confidential Information pursuant to a license granted hereunder, the receiving party agrees to return to the disclosing party all Confidential Information of the disclosing party, or, at the receiving party’s option destroy such Confidential Information and, thereafter, certify immediately to the disclosing party that all such Confidential Information has been returned or destroyed.

 

12

 

IN WITNESS WHEREOF, the parties have caused this Amended and Restated Agreement to be executed, effective as of the Restatement Date.

 

 

	
 
    	
GLAUKOS   CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
Dated:
    	
By:
    
	
 
    	
 
    
	
 
    	
Printed   Name:
    
	
 
    	
 
    
	
 
    	
Title:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DOSE   MEDICAL CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
Dated:
    	
By:
    
	
 
    	
 
    
	
 
    	
Printed   Name:
    
	
 
    	
 
    
	
 
    	
Title:
    

 

13

 

EXHIBIT A — DOSE LICENSED PATENTS

 

(Status as of July 10, 2014)

 

	
KMOB
   Ref. No.
   GLAUKO.
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent
   No
    	
 
    	
Issued:
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C3CP1
    	
 
    	
OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7708711
    	
 
    	
05/04/10
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C3CP1C1
    	
 
    	
OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8348877
    	
 
    	
01/08/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VRAU
    	
 
    	
APPARATUS AND METHOD FOR TREATING OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2006200392
    	
 
    	
11/25/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VR2AU
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2009202842
    	
 
    	
04/26/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001AUD3
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001JPD2
    	
 
    	
OCULAR IMPLANT WITH THERAPEUTIC DRUG
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5C1CP1
    	
 
    	
IMPLANT WITH INTRAOCULAR PRESSURE SENSOR FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7678065
    	
 
    	
03/16/10
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5CCP1DV1
    	
 
    	
METHOD OF MONITORING INTRAOCULAR PRESSURE AND TREATING AN OCULAR   DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8142364
    	
 
    	
03/27/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
5CCPDD
    	
 
    	
SYSTEM AND METHOD OF MONITORING INTRAOCULAR PRESSURE AND TREATING AN   OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
044A
    	
 
    	
INTRAOCULAR PHYSIOLOGICAL SENSOR
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
045A
    	
 
    	
IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING   SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
045P1WO
    	
 
    	
IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING   SAME
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
049PR
    	
 
    	
INTRAOCULAR DRUG DELIVERY IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
049PR2
    	
 
    	
INTRAOCULAR DRUG DELIVERY IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001P1C2
    	
 
    	
OCULAR IMPLANT WITH THERAPEUTIC AGENTS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
019NP
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
019EP
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
EP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    

 

A-1

 

	
KMOB
   Ref. No.
   GLAUKO.
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent
   No
    	
 
    	
Issued:
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
032A
    	
 
    	
INTRAOCULAR PHYSIOLOGICAL SENSOR
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036NP
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036AU
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036CA
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036CN
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
CN
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036EP
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
EP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036IN
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
IN
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
036JP
    	
 
    	
DRUG ELUTING OCULAR IMPLANT
    	
 
    	
JP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
037NP
    	
 
    	
UVEOSCLERAL DRUG DELIVERY IMPLANT AND METHODS FOR IMPLANTING THE SAME
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    

 

A-2

 

EXHIBIT B — GLAUKOS GROUP 1 LICENSED PATENTS

 

(Status as of July 10, 2014)

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001A
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6638239
    	
 
    	
10/28/03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001C1
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6955656
    	
 
    	
10/18/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001C2
    	
 
    	
L-SHAPED IMPLANT WITH BI-DIRECTIONAL FLOW
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6780164
    	
 
    	
8/24/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001C4
    	
 
    	
IMPLANT WITH ANCHOR
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7297130
    	
 
    	
11/20/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001CP1
    	
 
    	
GLAUCOMA TREATMENT DEVICE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6736791
    	
 
    	
5/18/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VAU
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2001245522
    	
 
    	
2/10/06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VCA
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VCAD1
    	
 
    	
APPARATUS AND METHOD FOR TREATING AN OCULAR DISORDER
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VDE
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
DE
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VEP
    	
 
    	
APPARATUS FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001EPD2
    	
 
    	
IMPLANT FOR TREATING OCULAR DISORDERS
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VREP
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
2078516
    	
 
    	
01/02/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VES
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
ES
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VFR
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
FR
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VGB
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
GB
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VIT
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
IT
    	
 
    	
Issued
    	
 
    	
1278492
    	
 
    	
4/29/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VJP
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
3985019
    	
 
    	
7/20/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001VRJP
    	
 
    	
APPARATUS AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5255214
    	
 
    	
4/26/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011A
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7135009
    	
 
    	
11/14/06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C1
    	
 
    	
IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7563241
    	
 
    	
7/21/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C1C1
    	
 
    	
SYSTEM FOR TREATING OCULAR DISORDERS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8075511
    	
 
    	
12/13/11
    

 

B-1

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C1D2C
    	
 
    	
OCULAR IMPLANT DELIVERY SYSTEM AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C1DV1
    	
 
    	
SELF-TREPHINING IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR   DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8062244
    	
 
    	
11/22/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C1DV2
    	
 
    	
OCULAR IMPLANT DELIVERY SYSTEM AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7857782
    	
 
    	
12/28/10
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C4
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8579846
    	
 
    	
11/12/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C5
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011C6
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011CP1
    	
 
    	
DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7867186
    	
 
    	
01/11/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011CP3
    	
 
    	
OCULAR IMPLANTS WITH ANCHORS AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7431710
    	
 
    	
10/7/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QAU
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2004264913
    	
 
    	
12/08/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QAUD1
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QAUD2
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QCA
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QEP
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
1651291
    	
 
    	
3/13/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QEPD1
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
2351589
    	
 
    	
11/6/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QJP
    	
 
    	
DEVICES AND METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5249513
    	
 
    	
4/19/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QJPD1
    	
 
    	
DEVICES FOR GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011QJPD2
    	
 
    	
DEVICES FOR GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VAU
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2002258754
    	
 
    	
11/30/06
    

 

B-2

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VCA
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2442652
    	
 
    	
01/04/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VCAD1
    	
 
    	
NON-LINEAR DELIVERY DEVICE AND OCULAR IMPLANT WITH CUTTING MEMBER
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2718294
    	
 
    	
6/17/2014
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VDE
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
DE
    	
 
    	
Issued
    	
 
    	
602 25 815.4-08
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VEP
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VEPD2
    	
 
    	
SYSTEM FOR TREATING OCULAR DISORDERS
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VES
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
ES
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VFR
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
FR
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VGB
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
GB
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VIE
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
IE
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VIT
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
IT
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VJP
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
4264704
    	
 
    	
2/27/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VNL
    	
 
    	
GLAUCOMA STENT FOR GLAUCOMA TREATMENT
    	
 
    	
NL
    	
 
    	
Issued
    	
 
    	
1418868
    	
 
    	
3/26/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VR2AU
    	
 
    	
IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2009251058
    	
 
    	
12/5/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VRAU
    	
 
    	
IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
AU
    	
 
    	
Issued
    	
 
    	
2006236060
    	
 
    	
1/7/10
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VRCA
    	
 
    	
SYSTEM AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VREP
    	
 
    	
SYSTEM FOR TREATING OCULAR DISORDERS
    	
 
    	
EP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011VRJP
    	
 
    	
SYSTEM FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5255402
    	
 
    	
4/26/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011JPD2
    	
 
    	
SYSTEM FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
JP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
011XEU
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000097431-0001/2/3
    	
 
    	
12/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
013A
    	
 
    	
MEDICAL DEVICE AND METHODS OF USE FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7094225
    	
 
    	
8/22/06
    

 

B-3

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
013C1
    	
 
    	
MEDICAL DEVICE AND METHODS OF USE FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7273475
    	
 
    	
9/25/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
013C1DV1
    	
 
    	
OCULAR IMPLANT WITH DOUBLE ANCHOR MECHANISM
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8337445
    	
 
    	
12/25/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
017A
    	
 
    	
GLAUCOMA STENT FOR TREATING GLAUCOMA AND METHODS OF USE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7331984
    	
 
    	
2/19/08
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
017C1
    	
 
    	
IMPLANT DELIVERY SYSTEM AND METHODS THEREOF FOR TREATING OCULAR   DISORDERS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
017C2
    	
 
    	
IMPLANT DELIVERY SYSTEM AND METHODS THEREOF FOR TREATING OCULAR   DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7879079
    	
 
    	
02/01/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
020A
    	
 
    	
FLUID INFUSION METHODS FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7186232
    	
 
    	
3/6/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
022A
    	
 
    	
COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7163543
    	
 
    	
1/16/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
022C1
    	
 
    	
COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7951155
    	
 
    	
5/31/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
029A
    	
 
    	
ANTERIOR CHAMBER DRUG-ELUTING OCULAR IMPLANT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
034A
    	
 
    	
TARGETED STENT PLACEMENT AND MULTI-STENT THERAPY
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7192412
    	
 
    	
3/20/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
035A
    	
 
    	
OCULAR IMPLANT WITH ANCHOR AND MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7488303
    	
 
    	
2/10/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
035C2
    	
 
    	
OCULAR IMPLANT WITH ANCHOR AND MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
035DV1
    	
 
    	
OCULAR IMPLANT WITH ANCHORING MECHANISM AND MULTIPLE OUTLETS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8007459
    	
 
    	
8/30/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
042PR
    	
 
    	
OCULAR IMPLANTS CONFIGURED TO STORE AND RELEASE STABLE DRUG   FORMULATIONS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
044DA
    	
 
    	
SURGICAL HANDPIECE
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
DES490152
    	
 
    	
5/18/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
044XEU
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0001
    	
 
    	
12/9/03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
044XEU2
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0002
    	
 
    	
12/9/03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
044XEU3
    	
 
    	
SURGICAL INSTRUMENTS
    	
 
    	
EU
    	
 
    	
Issued
    	
 
    	
000071071-0003
    	
 
    	
12/9/03
    

 

B-4

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
050PR1
    	
 
    	
IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING   SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
050PR2
    	
 
    	
IMPLANTS WITH CONTROLLED DRUG DELIVERY FEATURES AND METHODS OF USING   SAME
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099A
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8506515
    	
 
    	
08/13/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099C1
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099AUD1
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
AU
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099VCA
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
CA
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099VEP
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
EP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
099VJP
    	
 
    	
UVEOSCLERAL SHUNT AND METHODS FOR IMPLANTING SAME
    	
 
    	
JP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100A
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6450984
    	
 
    	
9/17/02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100C1
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6626858
    	
 
    	
9/30/03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100C1C1
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6827699
    	
 
    	
12/7/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100C1C2
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6827700
    	
 
    	
12/7/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100CC1C
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7850637
    	
 
    	
12/14/10
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100CC1C2
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8388568
    	
 
    	
03/05/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100CC1CD
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8771217
    	
 
    	
7/8/14
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100CC2C
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8152752
    	
 
    	
04/10/12
    

 

B-5

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100C7
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
100CPC1
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7220238
    	
 
    	
5/22/07
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VCA
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2368354
    	
 
    	
2/17/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VDE
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
DE
    	
 
    	
Issued
    	
 
    	
60019740.9
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VEP
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VEPD4
    	
 
    	
TRABECULOTOMY DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VES
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
ES
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VFR
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
FR
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VGB
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
GB
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VIN
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
IN
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VIT
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
IT
    	
 
    	
Issued
    	
 
    	
1173124
    	
 
    	
4/27/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VJP
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
3703721
    	
 
    	
7/29/05
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VR1JP
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
4688444
    	
 
    	
2/25/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VRCA
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
CA
    	
 
    	
Issued
    	
 
    	
2648346
    	
 
    	
12/4/2012
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VREP
    	
 
    	
SHUNT DEVICE FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
1477146
    	
 
    	
8/26/09
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VREP2
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VREP3
    	
 
    	
SHUNT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
EP
    	
 
    	
Issued
    	
 
    	
2116215
    	
 
    	
02/01/12
    

 

B-6

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
113VRJPD
    	
 
    	
SHUNT DEVICE FOR TREATING GLAUCOMA
    	
 
    	
JP
    	
 
    	
Issued
    	
 
    	
5323011
    	
 
    	
7/26/2013
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
119A
    	
 
    	
STENT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6464724
    	
 
    	
10/15/02
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
119C1
    	
 
    	
STENT DEVICE AND METHOD FOR TREATING GLAUCOMA
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
6783544
    	
 
    	
8/31/04
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11CP1C1
    	
 
    	
DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7879001
    	
 
    	
02/01/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11CP1C2
    	
 
    	
DEVICES AND METHODS FOR TREATMENT OF OCULAR DISORDERS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11CP2CP1
    	
 
    	
OCULAR DISORDER TREATMENT IMPLANTS WITH MULTIPLE OPENINGS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11P1C3
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11P1C4
    	
 
    	
OCULAR IMPLANT SYSTEMS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11CP3DV1
    	
 
    	
DRUG ELUTING OCULAR IMPLANT WITH ANCHOR AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8118768
    	
 
    	
2/21/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
11P3D1C1
    	
 
    	
OCULAR SYSTEM WITH ANCHORING IMPLANT AND THERAPEUTIC AGENT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
140A
    	
 
    	
SYSTEM AND METHOD FOR DELIVERING MULTIPLE OCULAR IMPLANTS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
140WO
    	
 
    	
SYSTEM FOR DELIVERING MULTIPLE OCULAR IMPLANTS
    	
 
    	
WO
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
155A
    	
 
    	
GONIOSCOPE FOR IMPROVED VIEWING
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8070290
    	
 
    	
12/06/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
157DA
    	
 
    	
GONIOSCOPIC SYSTEM INCLUDING AN OPTICAL ELEMENT ATTACHMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
D645489
    	
 
    	
9/20/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
171DA
    	
 
    	
GONIOSCOPIC SYSTEM INCLUDING AN OPTICAL ELEMENT ATTACHMENT
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
D645490
    	
 
    	
9/20/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
179A
    	
 
    	
SYSTEMS AND METHODS FOR DELIVERING AN OCULAR IMPLANT TO THE   SUPRACHOROIDAL SPACE WITHIN AN EYE
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    

 

B-7

 

	
KMOB
   Ref No.
   GLAUKO
    	
 
    	
Title of Invention
    	
 
    	
Country
    	
 
    	
Status
    	
 
    	
Patent No.
    	
 
    	
Issued
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
179WO
    	
 
    	
SYSTEMS AND METHODS FOR DELIVERING AN OCULAR IMPLANT TO THE   SUPRACHOROIDAL SPACE WITHIN AN EYE
    	
 
    	
WO
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
196A
    	
 
    	
GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT
    	
 
    	
US
    	
 
    	
Pending
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C4C11
    	
 
    	
OCULAR IMPLANT WITH ANCHOR AND METHODS THEREOF
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C4C12
    	
 
    	
METHOD OF DELIVERING AN IMPLANT FOR TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
8333742
    	
 
    	
12/18/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C4C13
    	
 
    	
SYSTEM AND METHOD FOR TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C4C2
    	
 
    	
METHOD OF DELIVERING AN IMPLANT FOR TREATING AN OCULAR DISORDER
    	
 
    	
US
    	
 
    	
Issued
    	
 
    	
7867205
    	
 
    	
01/11/11
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C2C3DV1
    	
 
    	
IMPLANT DELIVERY DEVICE AND METHODS THEREOF FOR TREATMENT OF OCULAR   DISORDERS
    	
 
    	
US
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    

 

B-8

 

EXHIBIT C — GLAUKOS GROUP 2 LICENSED PATENTS

 

(Status as of July 10, 2014)

 

	
KMOB Ref.
   No.
   GLAUKO.
    	
 
    	
Title of Invention
    	
 
    	
Status
    	
 
    	
Patent No
    	
 
    	
Issued:
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
001D1
    	
 
    	
OCULAR IMPLANT WITH THERAPEUTIC AGENT AND METHODS THEREOF
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
1C2C3
    	
 
    	
OCULAR IMPLANT WITH ANCHOR AND THERAPEUTIC AGENT
    	
 
    	
Issued
    	
 
    	
8273050
    	
 
    	
09/25/12
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
005A
    	
 
    	
BIFURCATABLE TRABECULAR SHUNT FOR GLAUCOMA TREATMENT
    	
 
    	
Issued
    	
 
    	
6666841
    	
 
    	
12/23/03
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
005C1
    	
 
    	
IMPLANT WITH PRESSURE SENSOR FOR GLAUCOMA TREATMENT
    	
 
    	
Issued
    	
 
    	
6981958
    	
 
    	
1/3/06
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
020C1
    	
 
    	
FLUID INFUSION METHODS FOR OCULAR DISORDER TREATMENT
    	
 
    	
Published
    	
 
    	
8617094
    	
 
    	
12/31/13
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
022C2
    	
 
    	
COMBINED TREATMENT FOR CATARACT AND GLAUCOMA TREATMENT
    	
 
    	
Published
    	
 
    	
 
    	
 
    	
 
    

 

C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]